Magnesium sulfate
Explore a selection of our essential drug information below, or:
Identification
- Summary
Magnesium sulfate is a drug used to treat convulsions during pregnancy, nephritis in children, magnesium deficiency, and tetany.
- Brand Names
- Concept Ob, Suflave, Suprep Bowel Prep Kit, Tis-U-sol
- Generic Name
- Magnesium sulfate
- DrugBank Accession Number
- DB00653
- Background
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
- Type
- Small Molecule
- Groups
- Approved, Investigational, Vet approved
- Structure
- Weight
- Average: 120.368
Monoisotopic: 119.936771076 - Chemical Formula
- MgO4S
- Synonyms
- Magnesium sulfate (1:1)
- Magnesium sulfate anhydrous
- Magnesium sulphate
- magnesium(II) sulfate
- Magnesiumsulfat
- MgSO4
Pharmacology
- Indication
Used for immediate control of life-threatening convulsions in the treatment of severe toxemias (pre-eclampsia and eclampsia) of pregnancy and in the treatment of acute nephritis in children. Also indicated for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those of hypocalcemia. Also used in uterine tetany as a myometriat relaxant.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Constipation ••• ••• Management of Convulsions •••••••••••• •••••••••• •••••••••• •••••••• Prophylaxis of Convulsions •••••••••••• •••••••••• •••••••••• •••••••• Management of Convulsions •••••••••••• •••••••••• •••••••••• •••••••• Treatment of Hypomagnesemia •••••••••••• •••••••••• •••••••••• •••••••• - Associated Therapies
- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Magnesium sulfate is a small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. Magnesium sulfate is gaining popularity as an initial treatment in the management of various dysrhythmias, particularly torsades de pointes, and dyrhythmias secondary to TCA overdose or digitalis toxicity.
- Mechanism of action
Magnesium is the second most plentiful cation of the intracellular fluids. It is essential for the activity of many enzyme systems and plays an important role with regard to neurochemical transmission and muscular excitability. Magnesium sulfate reduces striated muscle contractions and blocks peripheral neuromuscular transmission by reducing acetylcholine release at the myoneural junction. Additionally, Magnesium inhibits Ca2+ influx through dihydropyridine-sensitive, voltage-dependent channels. This accounts for much of its relaxant action on vascular smooth muscle.
Target Actions Organism AVoltage-dependent L-type calcium channel inhibitorblockerHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
25-30%
- Metabolism
None
- Route of elimination
Magnesium is excreted solely by the kidney at a rate proportional to the serum concentration and glomerular filtration.
- Half-life
43.2 hours (for newborns)
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
LD50 = 1200 mg/kg (rat, subcutaneous). May be harmful if swallowed. May act as an irritant. Adverse reactions include hypotension, ECG changes, diarrhea, urinary retention, CNS depression and respiratory depression.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The therapeutic efficacy of 1,2-Benzodiazepine can be increased when used in combination with Magnesium sulfate. Acarbose The risk or severity of hypoglycemia can be increased when Magnesium sulfate is combined with Acarbose. Acebutolol Magnesium sulfate may increase the arrhythmogenic activities of Acebutolol. Aceclofenac The risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Aceclofenac. Acemetacin The risk or severity of hyperkalemia can be increased when Magnesium sulfate is combined with Acemetacin. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Magnesium sulfate dihydrate 10NKG94IWF 17830-05-6 QSOMFNQEXNFPNU-UHFFFAOYSA-L Magnesium sulfate heptahydrate SK47B8698T 10034-99-8 WRUGWIBCXHJTDG-UHFFFAOYSA-L Magnesium sulfate monohydrate E2L2TK027P 14168-73-1 LFCFXZHKDRJMNS-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Magnesium cation ionic T6V3LHY838 22537-22-0 JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium unknown I38ZP9992A 7439-95-4 RSHAOIXHUHAZPM-UHFFFAOYSA-N Sulfate ion ionic 7IS9N8KPMG 14808-79-8 QAOWNCQODCNURD-UHFFFAOYSA-L - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous HF Acquisition Co LLC, DBA HealthFirst 2019-12-11 Not applicable US Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous Henry Schein, Inc. 2022-01-12 Not applicable US Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous Medical Purchasing Solutions, Llc 2000-08-08 Not applicable US Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous General Injectables and Vaccines, Inc. 2017-01-13 2024-02-29 US Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous Henry Schein, Inc. 2022-01-18 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image 50% Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous Hf Acquisition Co. Llc, Dba Health First 2018-08-25 Not applicable US Magnesium Sulfate Injection, solution 500 mg/1mL Intramuscular; Intravenous Hospira, Inc. 2006-11-28 Not applicable US Magnesium Sulfate Injection, solution 2 g/50mL Intravenous Mylan Institutional LLC 2020-10-02 Not applicable US Magnesium Sulfate Injection, solution 40 mg/1mL Intravenous Sun Pharmaceutical Industries, Inc. 2021-08-01 Not applicable US Magnesium Sulfate Injection, solution 2 g/50mL Intravenous Gland Pharma Limited 2020-07-10 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Assured Epsom Salt Granule 100 g/100g Oral Hefei Yatai Daily Chemical Products Co., Ltd. 2016-03-30 Not applicable US Assured Epsom Salt Granule 100 g/100g Oral Greenbrier International, Inc. 2016-06-14 Not applicable US Daily Care Epsom Salt Granule 100 g/100g Oral 1 Source Trading LLC 2021-06-03 Not applicable US DBL Magnesium Sulfate Concentrated Injection 49.3% Injection 2.47 g/5ml Intramuscular; Intravenous PFIZER PRIVATE LIMITED 1991-05-21 Not applicable Singapore Epsal Ointment 400 mg/1g Topical Press Chemical And Pharmaceutical Laboratories 1957-01-15 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminomix peripher Infusionslösung Magnesium sulfate heptahydrate (0.78 g/L) + Alanine (4.9 g/L) + Arginine (4.2 g/L) + Calcium chloride dihydrate (0.24 g/L) + D-glucose monohydrate (69.3 g/L) + Glycine (3.85 g/L) + Histidine (1.05 g/L) + Isoleucine (1.75 g/L) + Leucine (2.59 g/L) + Lysine acetate (3.26 g/L) + Methionine (1.51 g/L) + Phenylalanine (1.79 g/L) + Potassium chloride (1.41 g/L) + Proline (3.92 g/L) + Serine (2.28 g/L) + Sodium acetate trihydrate (1.16 g/L) + Sodium glycerophosphate hydrate (1.78 g/L) + Taurine (0.35 g/L) + Threonine (1.54 g/L) + Tryptophan (0.7 g/L) + Tyrosine (0.14 g/L) + Valine (2.17 g/L) Solution Intravenous Fresenius Kabi Austria Gmb H 2016-07-07 Not applicable Austria ANTIBIL POLVO Magnesium sulfate (21.13 g) + Rhubarb (0.43 g) + Sennosides (0.44 g) Powder, for suspension Oral LABORATORIOS NEO LTDA 2006-11-10 Not applicable Colombia Aqua De Folli Hair Booster Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Mini Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Pro Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aqua De Folli Hair Booster Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Mini Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Aqua De Folli Hair Booster Pro Magnesium sulfate (0.00024 g/100mL) + Sodium bicarbonate (0.006 g/100mL) + Zinc sulfate, unspecified form (0.0000022 g/100mL) Liquid Topical ROKIT HEALTHCARE Inc. 2020-09-24 Not applicable US Centratex Magnesium sulfate (6.9 mg/1) + Cupric sulfate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Iron (106 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Sodium ascorbate (200 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1) Capsule Oral Centurion Labs, LLC 2009-06-14 Not applicable US Concept DHA Magnesium sulfate (5 mg/1) + Ascorbic acid (25 mg/1) + Biotin (300 ug/1) + Cupric sulfate pentahydrate (2 mg/1) + Cyanocobalamin (12.5 ug/1) + Ferrous fumarate (17.5 mg/1) + Folic acid (1 mg/1) + Iron (17.5 mg/1) + Niacin (1.8 mg/1) + Omega-3-acid ethyl esters (200 mg/1) + Calcium pantothenate (5 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Riboflavin (3 mg/1) + Thiamine mononitrate (2 mg/1) + Zinc sulfate, unspecified form (10 mg/1) Capsule, liquid filled Oral U.S. Pharmaceutical Corporation 2009-06-24 Not applicable US
Categories
- ATC Codes
- A06AD04 — Magnesium sulfate
- A06AD — Osmotically acting laxatives
- A06A — DRUGS FOR CONSTIPATION
- A06 — DRUGS FOR CONSTIPATION
- A — ALIMENTARY TRACT AND METABOLISM
- D11AX — Other dermatologicals
- D11A — OTHER DERMATOLOGICAL PREPARATIONS
- D11 — OTHER DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- B05XA — Electrolyte solutions
- B05X — I.V. SOLUTION ADDITIVES
- B05 — BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
- B — BLOOD AND BLOOD FORMING ORGANS
- Drug Categories
- Agents causing hyperkalemia
- Agents that produce neuromuscular block (indirect)
- Alimentary Tract and Metabolism
- Analgesics
- Anesthetics
- Antiarrhythmic agents
- Anticonvulsants
- Blood and Blood Forming Organs
- Blood Substitutes and Perfusion Solutions
- Bradycardia-Causing Agents
- Calcium Channel Blockers
- Calcium-Regulating Hormones and Agents
- Cardiovascular Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Dermatologicals
- Diagnostic Agents
- Drugs for Constipation
- Electrolyte Solutions
- I.V. Solution Additives
- Laxatives
- Laxatives, magnesium containing
- Magnesium Compounds
- Magnesium Salts
- Membrane Transport Modulators
- Metal cations
- Metal divalent cations
- Mineral Supplements
- Miscellaneous Anticonvulsants
- Osmotic Laxatives
- Peripheral Nervous System Agents
- Replacement Preparations
- Reproductive Control Agents
- Sensory System Agents
- Sulfates
- Sulfur Acids
- Sulfur Compounds
- Sulfuric Acids
- Tests for Bile Duct Patency
- Tocolytic Agents
- Vasodilating Agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkaline earth metal sulfates. These are inorganic compounds in which the largest oxoanion is sulfate, and in which the heaviest atom not in an oxoanion is an alkaline earth metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkaline earth metal oxoanionic compounds
- Sub Class
- Alkaline earth metal sulfates
- Direct Parent
- Alkaline earth metal sulfates
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Alkaline earth metal sulfate / Inorganic oxide / Inorganic salt
- Molecular Framework
- Not Available
- External Descriptors
- magnesium salt, metal sulfate (CHEBI:32599)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- ML30MJ2U7I
- CAS number
- 7487-88-9
- InChI Key
- CSNNHWWHGAXBCP-UHFFFAOYSA-L
- InChI
- InChI=1S/Mg.H2O4S/c;1-5(2,3)4/h;(H2,1,2,3,4)/q+2;/p-2
- IUPAC Name
- magnesium(2+) sulfate
- SMILES
- [Mg++].[O-]S([O-])(=O)=O
References
- Synthesis Reference
Shinichi Yamamoto, Akifumi Sekitani, "BASIC MAGNESIUM SULFATE GRANULE, AND PROCESS FOR PRODUCTION THEREOF." U.S. Patent US20110042297, issued February 24, 2011.
US20110042297- General References
- Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, Rowe BH: Aerosolized magnesium sulfate for acute asthma: a systematic review. Chest. 2005 Jul;128(1):337-44. [Article]
- Yokoyama K, Takahashi N, Yada Y, Koike Y, Kawamata R, Uehara R, Kono Y, Honma Y, Momoi MY: Prolonged maternal magnesium administration and bone metabolism in neonates. Early Hum Dev. 2010 Mar;86(3):187-91. doi: 10.1016/j.earlhumdev.2010.02.007. Epub 2010 Mar 12. [Article]
- Wedig KE, Kogan J, Schorry EK, Whitsett JA: Skeletal demineralization and fractures caused by fetal magnesium toxicity. J Perinatol. 2006 Jun;26(6):371-4. [Article]
- Nassar AH, Sakhel K, Maarouf H, Naassan GR, Usta IM: Adverse maternal and neonatal outcome of prolonged course of magnesium sulfate tocolysis. Acta Obstet Gynecol Scand. 2006;85(9):1099-103. [Article]
- Malaeb SN, Rassi AI, Haddad MC, Seoud MA, Yunis KA: Bone mineralization in newborns whose mothers received magnesium sulphate for tocolysis of premature labour. Pediatr Radiol. 2004 May;34(5):384-6. Epub 2004 Feb 18. [Article]
- Matsuda Y, Maeda Y, Ito M, Sakamoto H, Masaoka N, Takada M, Sato K: Effect of magnesium sulfate treatment on neonatal bone abnormalities. Gynecol Obstet Invest. 1997;44(2):82-8. [Article]
- Schanler RJ, Smith LG Jr, Burns PA: Effects of long-term maternal intravenous magnesium sulfate therapy on neonatal calcium metabolism and bone mineral content. Gynecol Obstet Invest. 1997;43(4):236-41. [Article]
- Santi MD, Henry GW, Douglas GL: Magnesium sulfate treatment of preterm labor as a cause of abnormal neonatal bone mineralization. J Pediatr Orthop. 1994 Mar-Apr;14(2):249-53. [Article]
- Holcomb WL Jr, Shackelford GD, Petrie RH: Magnesium tocolysis and neonatal bone abnormalities: a controlled study. Obstet Gynecol. 1991 Oct;78(4):611-4. [Article]
- Cumming WA, Thomas VJ: Hypermagnesemia: a cause of abnormal metaphyses in the neonate. AJR Am J Roentgenol. 1989 May;152(5):1071-2. [Article]
- Lamm CI, Norton KI, Murphy RJ, Wilkins IA, Rabinowitz JG: Congenital rickets associated with magnesium sulfate infusion for tocolysis. J Pediatr. 1988 Dec;113(6):1078-82. [Article]
- McGuinness GA, Weinstein MM, Cruikshank DP, Pitkin RM: Effects of magnesium sulfate treatment on perinatal calcium metabolism. II. Neonatal responses. Obstet Gynecol. 1980 Nov;56(5):595-600. [Article]
- Riaz M, Porat R, Brodsky NL, Hurt H: The effects of maternal magnesium sulfate treatment on newborns: a prospective controlled study. J Perinatol. 1998 Nov-Dec;18(6 Pt 1):449-54. [Article]
- External Links
- Human Metabolome Database
- HMDB0014791
- KEGG Drug
- D01108
- PubChem Compound
- 24083
- PubChem Substance
- 46508411
- ChemSpider
- 22515
- 1311625
- ChEBI
- 32599
- ChEMBL
- CHEMBL2021423
- Therapeutic Targets Database
- DAP000201
- PharmGKB
- PA450302
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Magnesium_sulfate
- MSDS
- Download (72.1 KB)
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Active Not Recruiting Not Available Anesthesia and Analgesia / Bariatric Surgery Candidates / Magnesium Sulphate 1 somestatus stop reason just information to hide Not Available Completed Not Available Asthma Attack 1 somestatus stop reason just information to hide Not Available Completed Not Available Asthma / Chronic Obstructive Pulmonary Disease (COPD) 1 somestatus stop reason just information to hide Not Available Completed Not Available Bowel preparation therapy 1 somestatus stop reason just information to hide Not Available Completed Not Available Breast Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Abraxis pharmaceutical products
- Hospira inc
- Packagers
- Denison Pharmaceuticals Inc.
- Gallipot
- Hospira Inc.
- Pharmakon
- Pharmedium
- QOL Medical
- Spectrum Pharmaceuticals
- Vi-Jon Laboratories Inc.
- Walgreen Co.
- Dosage Forms
Form Route Strength Powder Oral Liquid Topical Powder, for suspension Oral Powder, for solution Oral Injection, solution Parenteral 200 mg Injection, solution Parenteral Solution Parenteral 1.00 g Injection Intramuscular; Intravenous 2.47 g/5ml Injection, solution, concentrate Intramuscular; Intravenous 493 mg/mL Capsule Cutaneous; Oral Capsule, liquid filled Oral Injection, solution Intravenous Injection Intrathecal Liquid Oral Ointment Topical 400 mg/1g Crystal Oral; Topical 1 g/1g Granule Oral 1 g/1g Granule Oral 100 kg/100kg Granule Oral; Topical 1 g/1g Granule Oral; Topical 1.81 kg/100kg Granule, for solution Oral; Topical 1 g/1g Granule, for solution Oral; Topical 100 g/100g Powder, for solution Oral 100 % Powder Topical 12 g/12g Granule Topical 2.72 kg/2.72kg Granule Oral; Topical 100 g/100g Powder Oral 100 % Powder Oral Granule, for solution Oral 1 g/1g Powder, for solution Oral 1000 mg/1g Injection, solution, concentrate Intramuscular; Intravenous 200 MG/ML Injection, solution, concentrate Intramuscular; Intravenous 400 MG/ML Emulsion Parenteral 20.000 g Injection, emulsion Intravenous Injection Intravenous Injection Intravenous 1.6 g/l Tablet, effervescent Oral Syrup Oral Solution Intramuscular 1.00 g Granule Oral 100 g/100g Solution Parenteral 0.100 g Injection, solution Intravenous Injection, solution, concentrate Intravenous Injection, solution Parenteral 493 mg/5mL Injection, solution Parenteral 985.9 mg/2mL Injection Intravenous 40 mg/1mL Injection, solution Intramuscular; Intravenous 500 mg/1mL Injection, solution Intravenous 2 g/50mL Injection, solution Intravenous 20 g/250mL Injection, solution Intravenous 20 g/500mL Injection, solution Intravenous 4 g/50mL Injection, solution Intravenous 4 g/100mL Injection, solution Intravenous 40 mg/1mL Injection, solution Intravenous 80 mg/1mL Liquid Topical 45 % Injection, solution Intravenous 1 g/100mL Solution Intravenous Injection Intravenous 1 g/100mL Injection, solution Intravenous 10 mg/1mL Injection, solution Intravenous 2 g/100mL Injection Intravenous 2 g/50mL Injection Intravenous 20 g/500mL Injection Intravenous 4 g/100mL Injection Intravenous 4 g/50mL Injection Intravenous 40 g/1000mL Injection, solution Intravenous 40 g/1000mL Solution Intravenous 40 mg / mL Solution Intravenous 80 mg / mL Liquid Intramuscular 500 mg / mL Liquid Intramuscular; Intravenous 500 mg / mL Liquid Intramuscular; Intravenous 200 mg / mL Solution Intramuscular; Intravenous 500 mg / mL Solution Intravenous 493 mg / mL Solution Parenteral 4929.5 mg/10mL Solution Parenteral 5000 mg/10mL Injection, solution Parenteral 100 mg/ml Injection, solution Parenteral 200 mg/ml Solution Intramuscular; Intravenous 15 % Solution Intramuscular; Intravenous 1.2 mEq/ml Solution Intravenous 1.5 g Powder Oral 26.000 g Injection, solution Parenteral 1 g/10ml Solution Parenteral 5 g/10ml Injection Intravenous 200 mg Injection Intravenous 400 mg Granule, for solution Oral; Topical 1 kg/1kg Liquid Intravenous Powder Topical 10 g/10g Crystal Oral; Topical 100 g/100g Injection Intravenous Injection Intravenous 40 % For solution Topical 1 kg/1kg Granule Oral 3.63 kg/3.63kg Granule, for solution Oral 1 kg/1kg Emulsion Intravenous Emulsion Intravenous 13.000 g Solution Oral Emulsion Parenteral Kit Oral Kit; powder, for solution Oral Injection Intravenous 2 g Solution Intravenous 2 g Solution Parenteral 2 g Solution Intravenous 2000 mg Solution, concentrate Oral Tablet Oral Capsule Oral Irrigant Irrigation Solution Irrigation Liquid Irrigation Injection, solution Intravenous 1500 mg/10ml Capsule, gelatin coated Oral Suspension Tablet, film coated Solution 100 mg/1ml Solution 500 mg/1ml - Prices
Unit description Cost Unit Elliotts b solution ampule 4.71USD ml Magnesium Sulfate 50% Solution 2ml Vial 0.92USD vial Magnesium sulfate powder 0.29USD g Magnesium-ns 6 g/50 ml bag 0.29USD ml Magnesium-ns 4 g/50 ml bag 0.27USD ml Magnesium-ns 3 g/50 ml bag 0.26USD ml Magnesium sulfate-ns 2 gm bag 0.25USD ml Magnesium sulfate-ns 1 gm bag 0.24USD ml Magnesium-d5w 1 gm/100 ml soln 0.07USD ml Magnesium-lr 20 g/500 ml 0.03USD ml Magnesium-lr 40 g/500 ml bag 0.03USD ml Magnesium-lr 50 g/500 ml bag 0.02USD ml Epsom salt 100% powder 0.01USD g Magnesium sulf 4% iv soln 0.01USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6946149 No 2005-09-20 2023-03-07 US US10143656 No 2018-12-04 2037-08-04 US US11033498 No 2021-06-15 2037-08-04 US US11382864 No 2017-08-04 2037-08-04 US US11638697 No 2017-08-04 2037-08-04 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 1124 °C (decomposition) Not Available water solubility 710 mg/mL Not Available logP -0.91 Not Available - Predicted Properties
Property Value Source logP -0.84 Chemaxon pKa (Strongest Acidic) -3 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 80.26 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 11.53 m3·mol-1 Chemaxon Polarizability 5.81 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.7487 Blood Brain Barrier + 0.9646 Caco-2 permeable - 0.6267 P-glycoprotein substrate Non-substrate 0.9137 P-glycoprotein inhibitor I Non-inhibitor 0.9194 P-glycoprotein inhibitor II Non-inhibitor 0.9904 Renal organic cation transporter Non-inhibitor 0.9521 CYP450 2C9 substrate Non-substrate 0.8775 CYP450 2D6 substrate Non-substrate 0.8213 CYP450 3A4 substrate Non-substrate 0.7007 CYP450 1A2 substrate Non-inhibitor 0.7767 CYP450 2C9 inhibitor Non-inhibitor 0.7602 CYP450 2D6 inhibitor Non-inhibitor 0.9115 CYP450 2C19 inhibitor Non-inhibitor 0.7547 CYP450 3A4 inhibitor Non-inhibitor 0.9759 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9577 Ames test Non AMES toxic 0.5773 Carcinogenicity Carcinogens 0.8111 Biodegradation Ready biodegradable 0.943 Rat acute toxicity 2.4160 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7988 hERG inhibition (predictor II) Non-inhibitor 0.9446
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-014i-0900000000-ecce6224eba6c0478dfd - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- InhibitorBlocker
- Curator comments
- The magnesium regulates the channel gating by binding to the EF-hand motif region in the COOH-terminal tail of the α-subunit of the channel.
- General Function
- Pore-forming, alpha-1C subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents (PubMed:11741969, PubMed:12176756, PubMed:12181424, PubMed:15454078, PubMed:15863612, PubMed:16299511, PubMed:17071743, PubMed:17224476, PubMed:20953164, PubMed:23677916, PubMed:24728418, PubMed:26253506, PubMed:27218670, PubMed:29078335, PubMed:29742403, PubMed:30023270, PubMed:30172029, PubMed:34163037, PubMed:7737988, PubMed:8099908, PubMed:8392192, PubMed:9013606, PubMed:9087614, PubMed:9607315). Mediates influx of calcium ions into the cytoplasm, and thereby triggers calcium release from the sarcoplasm (By similarity). Plays an important role in excitation-contraction coupling in the heart. Required for normal heart development and normal regulation of heart rhythm (PubMed:15454078, PubMed:15863612, PubMed:17224476, PubMed:24728418, PubMed:26253506). Required for normal contraction of smooth muscle cells in blood vessels and in the intestine. Essential for normal blood pressure regulation via its role in the contraction of arterial smooth muscle cells (PubMed:28119464). Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group (Probable)
- Specific Function
- alpha-actinin binding
Components:
References
- Brunet S, Scheuer T, Klevit R, Catterall WA: Modulation of CaV1.2 channels by Mg2+ acting at an EF-hand motif in the COOH-terminal domain. J Gen Physiol. 2005 Oct;126(4):311-23. doi: 10.1085/jgp.200509333. Epub 2005 Sep 12. [Article]
- Bara M, Guiet-Bara A: Magnesium regulation of Ca2+ channels in smooth muscle and endothelial cells of human allantochorial placental vessels. Magnes Res. 2001 Mar;14(1-2):11-8. [Article]
- Kuo CC, Hess P: Block of the L-type Ca2+ channel pore by external and internal Mg2+ in rat phaeochromocytoma cells. J Physiol. 1993 Jul;466:683-706. [Article]
- Zhao M, Feng R, Shao D, Liu S, Lei M, Wang H, Sun X, Guo F, Hu H, Kameyama M, Hao L: Mg(2+)-dependent facilitation and inactivation of L-type Ca(2+) channels in guinea pig ventricular myocytes. J Pharmacol Sci. 2015 Nov;129(3):143-9. doi: 10.1016/j.jphs.2015.08.001. Epub 2015 Aug 7. [Article]
- Lin CY, Tsai PS, Hung YC, Huang CJ: L-type calcium channels are involved in mediating the anti-inflammatory effects of magnesium sulphate. Br J Anaesth. 2010 Jan;104(1):44-51. doi: 10.1093/bja/aep336. [Article]
Drug created at June 13, 2005 13:24 / Updated at October 07, 2024 17:58